NUTRITIONAL PRIMARY PREVENTION OF TYPE I DIABETES IN CHILDREN

儿童 I 型糖尿病的营养一级预防

• 批准号: 7603388
• 负责人: Neil H. White
• 金额: $ 0.72万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603388
• 关键词: Affect; Autoimmunity; Breast Feeding; Cattle; Child; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Double-Blind Method; First Degree Relative; Funding; Genotype; Glucose Intolerance; Grant; Immunologic Markers; Incidence; Institution; Insulin-Dependent Diabetes Mellitus; Islet Cell; Islets of Langerhans; Life; Mothers; Newborn Infant; Nutritional; Primary Prevention; Randomized; Randomized Controlled Trials; Research; Research Personnel; Resources; Risk; Source; United States National Institutes of Health; Weaning; base; casein hydrolysate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multinational, multicenter, double-blinded, randomized controlled trial to determine whether weaning to a casein hydrolysate formula during at least the first 6 months of life reduces the incidence of type 1 diabetes in genetically susceptible children. Newborn infants, who have an increased risk-associated HLA genotype and an affected first degree relative, will be randomly assigned to receive either a cow's mild-based formula (Enfamil) or a casein hydrolysate formula (Nutramigen) for the first 6-8 months of life. The mother's breast feeding wishes will not be interrupted. Subjects will be followed for 5 years (10 years if funding allows) for the presence of immunologic markers of islet cell autoimmunity and the development of diabetes and/or glucose intolerance.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项跨国，多中心，双盲，随机对照试验，可以确定在至少在生命的前6个月内向酪蛋白水解剂公式断奶是否会降低遗传易感儿童中1型糖尿病的发生率。 新生儿的婴儿与风险相关的HLA基因型增加，并且是受影响的一级亲戚，将随机分配接受奶牛的温和式配方（Enfamil）或酪蛋白水解物配方（Nutramigen），在生命的前6-8个月中。 母亲的母乳喂养愿望不会中断。 对受试者的存在5年（如果允许资金允许的话，将遵循10年），以使胰岛细胞自动免疫的免疫学标记和糖尿病和/或葡萄糖不耐受的发展。